Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19

Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazato, Yusuke, Yamamoto, Kei, Nakaya, Yuichiro, Morioka, Shinichiro, Takeuchi, Junko S., Takamatsu, Yuki, Maeda, Kenji, Kimura, Moto, Sugiura, Wataru, Mitsuya, Hiroaki, Yano, Masao, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940576/
https://www.ncbi.nlm.nih.gov/pubmed/35337728
http://dx.doi.org/10.1016/j.jiac.2022.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940576/
https://www.ncbi.nlm.nih.gov/pubmed/35337728
http://dx.doi.org/10.1016/j.jiac.2022.03.002

Ejemplares similares